# Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

> **NCT02685267** · PHASE2 · TERMINATED · sponsor: **Prostate Cancer Clinical Trials Consortium** · enrollment: 9 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Enzalutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02685267
- **Lead sponsor:** Prostate Cancer Clinical Trials Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02685267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02685267, "Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02685267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*